Source - LSE Non-Regulatory
RNS Number : 1899G
Abingdon Health PLC
23 July 2021

Exclusive Lateral Flow Manufacturing Agreement with BioSure UK Limited


York, U.K. 23 July 2021:  Abingdon Health plc (AIM: ABDX) ("Abingdon" or "the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, today announces that it has signed an exclusive manufacturing agreement with BioSure Limited ("BioSure"), a UK company specialising in the provision of rapid in-vitro diagnostic testing solutions.


Under the terms of the exclusive agreement, Abingdon will manufacture BioSure's own lateral flow tests in the field of COVID19. The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon's York and Doncaster sites.   


Chris Yates, CEO of Abingdon Health, commented: "We are delighted to be supporting BioSure and building on our long-term collaboration with the BioSure team. We are committed to supporting the deployment of these much needed lateral flow test to the UK and international markets."


Brigette Bard, CEO of BioSURE, commented: "We are thrilled to be continuing to build our portfolio of products with Abingdon. BioSure is committed to delivering British developed tests to the global market and Abingdon are our ideal partner to manufacture our world-leading products."




Abingdon Health plc


Chris Yates

Chief Executive Officer

Via Consilium


Dr Chris Hand

Non-Executive Chairman


Melanie Ross

Chief Financial Officer





Financial PR

Tel: +44 (0) 7720 088 468


Matthew Neal


Mary-Jane Elliott             

Davide Salvi


About Abingdon Health


Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.


The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.


Founded in 2008, Abingdon Health is headquartered in York, England.


About BioSure (UK) Limited


BioSure (UK) Limited are the manufacturers of the first CE marked HIV Self-Test for personal use giving results in minutes. Since launching in 2015, the BioSURE HIV Self Test has helped people throughout the UK and the world, to #knowyourstatus. Since the beginning of the COVID-19 pandemic, BioSure have pivoted their expertise and now have a range of UK developed and manufactured COVID-19 tests, which are available for professional use in the UK and international markets.


Since launching the world's first approved blood-based HIV self-test, BioSure has worked with governments, communities, and individuals across the world, generating conversations, giving people a choice of being able to test themselves and know their own status on their own terms and just as importantly, giving people the confidence to make informed choices. 




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.